Inhibtor Therapeutics

Inhibitor Therapeutics is a pharmaceutical development company that focuses on the development and commercialization of innovative therapies for patients with cancer and non-cancerous proliferation disorders. Its main focus is to advance its lead product, SUBA-Itraconazole, a patented, oral formulation of the marketed, well-understood, anti-fungal drug, Itraconazole, for treatment of prostate and lung cancers.

Inhibitor is the exclusive U.S. licensee of SUBA-Itraconazole in many fields which include prostate and lung cancer. Clinical studies have shown its lead product, SUBA-Itraconazole to have greater bioavailability than generic itraconazole, a drug that was approved by FDA for the treatment of certain fungal infections.

.